The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Subscribe To Our Newsletter & Stay Updated
